Trade

with

Neurocrine Biosciences Inc
(NASDAQ: NBIX)
AdChoices
16.57
-0.09
-0.54%
After Hours :
16.57
0.00
0.00%

Open

16.60

Previous Close

16.66

Volume (Avg)

357.28k (528.17k)

Day's Range

16.28-16.84

52Wk Range

8.57-20.29

Market Cap.

1.26B

Dividend Rate ( Yield )

-

Beta

-0.02

Shares Outstanding

75.92M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 2.92M

    • Net Income

    • -46.09M

    • Market Cap.

    • 1.26B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -3,221.11

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.02

    • Forward P/E

    • -28.25

    • Price/Sales

    • 833.33

    • Price/Book Value

    • 5.34

    • Price/Cash flow

    • -28.25

      • EBITDA

      • -49.01M

      • Return on Capital %

      • -21.15

      • Return on Equity %

      • -25.21

      • Return on Assets %

      • -21.15

      • Book Value/Share

      • 3.12

      • Shares Outstanding

      • 75.92M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.04 (12/29/1995)

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 25.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 0.07

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -5.99

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 64.72

            • Pre-Tax Margin

            • -3,221.11

            • 13.77

            • Net Profit Margin

            • -3,221.11

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -654.60

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 16.39

              • 1.52

              • Quick Ratio

              • 16.39

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.14

              • 1.91

              • Book Value/Share

              • 3.12

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -24.88

                • 63.69

                • P/E Ratio 5-Year High

                • -30.30

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.90

                • 19.71

                • Price/Sales Ratio

                • 833.33

                • 3.57

                • Price/Book Value

                • 5.34

                • 3.35

                • Price/Cash Flow Ratio

                • -28.25

                • 21.41

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -25.21

                    (-50.70)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -21.15

                    (-11.60)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -25.21

                    (-28.60)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • 0.01

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -49.68M
                  Operating Margin
                  -1,701.88
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -28.25
                  Ownership

                  Institutional Ownership

                  98.32%

                  Top 10 Institutions

                  59.84%

                  Mutual Fund Ownership

                  63.09%

                  Float

                  73.26%

                  5% / Insider Ownership

                  1.93%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Health Sciences Fund

                  •  

                    4,038,700

                  • -0.30

                  • 5.32

                  • T. Rowe Price New Horizons Fund

                  •  

                    3,684,600

                  • -0.11

                  • 4.85

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,582,851

                  • 0.00

                  • 4.72

                  • Bb Biotech AG

                  •  

                    3,086,552

                  • 3.00

                  • 4.07

                  • Fidelity® Select Health Care Portfolio

                  •  

                    2,000,000

                  • 0.00

                  • 2.63

                  • Franklin Biotechnology Discovery

                  •  

                    1,513,300

                  • 29.86

                  • 1.99

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,202,062

                  • 0.00

                  • 1.58

                  • iShares Russell 2000 (AU)

                  •  

                    1,177,799

                  • -1.02

                  • 1.63

                  • VA CollegeAmerica Small Cap World

                  •  

                    1,150,200

                  • 0.00

                  • 1.52

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    1,115,382

                  • 0.02

                  • 1.47

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    10,550,755

                  • +0.70%

                  • 13.90

                  • T. Rowe Price Associates, Inc.

                  •  

                    10,255,239

                  • -0.02%

                  • 13.51

                  • Orbimed Advisors, LLC

                  •  

                    4,675,700

                  • -14.22%

                  • 6.16

                  • Perceptive Advisors LLC

                  •  

                    4,599,867

                  • -0.42%

                  • 6.06

                  • BB Biotech AG

                  •  

                    3,086,552

                  • +3.00%

                  • 4.07

                  • Bellevue Asset Management AG

                  •  

                    3,086,552

                  • +3.00%

                  • 4.07

                  • BlackRock Fund Advisors

                  •  

                    2,577,323

                  • -8.23%

                  • 3.39

                  • Vanguard Group, Inc.

                  •  

                    2,215,157

                  • -0.27%

                  • 2.92

                  • Franklin Advisers, Inc.

                  •  

                    2,204,200

                  • 0.00%

                  • 2.90

                  • State Street Corp

                  •  

                    2,171,880

                  • -3.20%

                  • 2.86

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Growth

                  Neurocrine Biosciences, Inc., a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and en...moredocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is...more currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.lessless

                  Key People

                  Dr. Kevin C. Gorman,PhD

                  CEO/Director/President

                  Dr. William H. Rastetter,PhD

                  Chairman of the Board/Director

                  Timothy P. Coughlin

                  CFO/Chief Accounting Officer/Vice President

                  Gary A. Lyons

                  Director

                  Corinne H. Nevinny

                  Director

                  • Neurocrine Biosciences Inc

                  • 12780 El Camino Real

                  • San Diego, CA 92130

                  • USA.Map

                  • Phone: +1 858 617-7600

                  • Fax: +1 858 617-7601

                  • neurocrine.com

                  Incorporated

                  1992

                  Employees

                  81

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: